|Bid||15.22 x 2900|
|Ask||15.18 x 800|
|Day's range||12.62 - 15.28|
|52-week range||12.62 - 56.74|
|Beta (5Y monthly)||1.76|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2022 - 04 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||58.38|
Investors are rattled by the FDA's request for an out-of-the-ordinary meeting dedicated to scrutinizing the company's latest drug approval request.
A new call from a well-known Wall Street firms casts a fresh shadow of doubt on the drugmaker's actual revenue prospects.
It is now my pleasure to introduce your host, Jenna Bosco, Senior Vice President, Corporate Communications. Following our safe harbor statement, Mike will provide an overview of our recent corporate developments as well as provide an update on the current pivotal programs and key remaining goals for 2021.